Proteomic Analysis in Lung Tissue of Smokers and COPD Patients

In, Kwang Ho; Kim, Je Hyeong; Lee, Sang Yeub; Shin, Chol; Shim, Jae Jeong; Kang, Kyung Ho; Yoo, Se Hwa; Kim, Chul‐Hwan; Kim, Han Kyeom; Lee, Sang Hoon; Uhm, Chang Sub

doi:10.1378/chest.08-1583

Cited by 74 publications

(66 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found that it was upregulated in mice by cigarette smoke with long-term exposure [21]. LEE et al [95], using proteomic analysis of lung tissue, found upregulation of MMP-13 in the lungs of COPD patients. Expression was confirmed by immunohistochemistry, which showed staining of macrophages and type II alveolar epithelial cells.…”

Section: Series: Mmps In Lung Health and Diseasementioning

confidence: 60%

Matrix metalloproteinases in COPD

Churg

Zhou²,

Wright³

2011

European Respiratory Journal

234

116

View full text Add to dashboard Cite

There is considerable evidence that matrix metalloproteinases (MMPs) are up-and/or downregulated in chronic obstructive pulmonary disease (COPD), particularly in emphysema, in which they probably participate in proteolytic attack on the alveolar wall matrix. Recent data suggest that MMPs also have major roles in driving inflammation or shutting it down, as well as modifying the release of fibrogenic growth factors, processes that are important in the genesis of the various lesions of COPD. In cigarette smoke-induced animal models of emphysema, MMP-12 appears to play a consistent and important role, whereas the data for other MMPs are difficult to interpret. In human lungs, evidence for a role for MMPs is more tenuous and there are numerous contradictions in the literature. Little is known about the effects of MMPs in small airway remodelling, smokeinduced pulmonary hypertension and chronic bronchitis, but MMP-12 participates in experimental small airway modelling. To date, the accumulated data suggest that selective inhibition of MMP-12 might be a viable therapy for emphysema and small airway remodelling, but subtle differences in the functions of MMP-12 in animals and humans mandate caution with this approach. Whether inhibition of other MMPs might be useful is unclear.

show abstract

Section: Series: Mmps In Lung Health and Diseasementioning

confidence: 60%

Matrix metalloproteinases in COPD

Churg

Zhou²,

Wright³

2011

European Respiratory Journal

234

116

View full text Add to dashboard Cite

show abstract

“…Proteomics is a nonbiased screening technique that has been used to investigate various sample types including bronchoalveolar lavage fluid (BALF) (21,28,36), induced sputum (10,14,23,24), and lung tissue (17,26) to identify novel markers for COPD. In recent proteomic studies from our laboratory the major findings included an elevation of surfactant protein-A (SP-A) and a decrease of specific variants of the receptor for advanced glycation end products (RAGE) in lung tissue (25,26) and polymeric immunoglobulin receptor in sputum samples from patients with COPD (24).…”

mentioning

confidence: 99%

Elevated sputum BPIFB1 levels in smokers with chronic obstructive pulmonary disease: a longitudinal study

Gao

Ohlmeier

Nieminen

et al. 2015

American Journal of Physiology-Lung Cellular and Molecular Phys

View full text Add to dashboard Cite

-A previous study involving a proteomic screen of induced sputum from smokers and patients with chronic obstructive pulmonary disease (COPD) demonstrated elevated levels of bactericidal/permeability-increasing foldcontaining protein B1 (BPIFB1). The aim of the present study was to further evaluate the association of sputum BPIFB1 levels with smoking and longitudinal changes in lung function in smokers with COPD. Sputum BPIFB1 was characterized by two-dimensional gel electrophoresis and mass spectrometry. The expression of BPIFB1 in COPD was investigated by immunoblotting and immunohistochemistry using sputum and lung tissue samples. BPIFB1 levels were also assessed in induced sputum from nonsmokers (n ϭ 31), smokers (n ϭ 169), and patients with COPD (n ϭ 52) via an ELISA-based method. The longitudinal changes in lung function during the 4-year follow-up period were compared with the baseline sputum BPIFB1 levels. In lung tissue samples, BPIFB1 was localized to regions of goblet cell metaplasia. Secreted and glycosylated BPIFB1 was significantly elevated in the sputum of patients with COPD compared with that of smokers and nonsmokers. Sputum BPIFB1 levels correlated with pack-years and lung function as measured by forced expiratory volume in 1 s (FEV 1) % predicted and FEV1/FVC (forced vital capacity) at baseline and after the 4-year follow-up in all participants. The changes in lung function over 4 years were significantly associated with BPIFB1 levels in current smokers with COPD. In conclusion, higher sputum concentrations of BPIFB1 were associated with changes of lung function over time, especially in current smokers with COPD. BPIFB1 may be involved in the pathogenesis of smokingrelated lung diseases.

show abstract

“…By analogy with IS and EBC, for example, high levels of surfactant protein A were also detected in COPD lung, but not in normal and fibrotic lungs [23]. Using MALDI-TOF-MS analysis, Lee et al showed that the expression of matrix metalloproteinase-13 (MMP-13) and thioredoxin-like 2 was increased in COPD lung tissues [24]. MMP-13, a proteolytic enzyme implicated in tissue damage and remodeling, was predominantly expressed in alveolar macrophages and type II pneumocytes.…”

Section: Lung Tissuesmentioning

confidence: 99%

Application of Proteomics and Peptidomics to COPD

Pelaia

Terracciano

Vatrella

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a complex disorder involving both airways and lung parenchyma, usually associated with progressive and poorly reversible airflow limitation. In order to better characterize the phenotypic heterogeneity and the prognosis of patients with COPD, there is currently an urgent need for discovery and validation of reliable disease biomarkers. Within this context, proteomic and peptidomic techniques are emerging as very valuable tools that can be applied to both systemic and pulmonary samples, including peripheral blood, induced sputum, exhaled breath condensate, bronchoalveolar lavage fluid, and lung tissues. Identification of COPD biomarkers by means of proteomic and peptidomic approaches can thus also lead to discovery of new molecular targets potentially useful to improve and personalize the therapeutic management of this widespread respiratory disease.

show abstract

Proteomic Analysis in Lung Tissue of Smokers and COPD Patients

Cited by 74 publications

References 31 publications

Matrix metalloproteinases in COPD

Matrix metalloproteinases in COPD

Elevated sputum BPIFB1 levels in smokers with chronic obstructive pulmonary disease: a longitudinal study

Application of Proteomics and Peptidomics to COPD

Contact Info

Product

Resources

About